Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Production & Manufacturing
Manufacturing
Return to: PBR Home | Production & Manufacturing | Manufacturing | News
Search Refinements

Manufacturing News

View news from other Pharmaceutical sectors:
151-165 of 2220 results
Lonza, Renova sign manufacturing deal for clinical supply of RT-100 gene therapy
Lonza Houston and Renova Therapeutics have entered into a Manufacturing Services Agreement to develop a scalable manufacturing process and produce cGMP-grade RT-100 (Ad5.hAC6) Drug Product for use in Renova’s future clinical trials.
Production & Manufacturing > Manufacturing > News
Mylan offers to buy Meda for $7.2bn
By PBR Staff Writer
Generic drug maker Mylan has agreed to acquire Swedish specialty pharmaceutical firm Meda Aktiebolag in a $7.2bn cash-and-stock transaction.
Production & Manufacturing > Manufacturing > News
UK health agency rejects Sanofi’s cholesterol drug
By PBR Staff Writer
UK’s National Institute of Health and Clinical Excellence (NICE) has recommended that patients with high-cholesterol should not take Sanofi and Regeneron’s new cholesterol lowering injection Praluent, but backed Amgen’s similar drug Repatha.
Production & Manufacturing > Manufacturing > News
Cigna and Aetna sign pay-for-performance deal with Novartis for Entresto drug
By PBR Staff Writer
US-based health insurance companies Cigna and Aetna have signed contracts with Swiss drug manufacturer Novartis for a performance-based price for the company’s new heart drug Entresto.
Production & Manufacturing > Manufacturing > News
EU drug agency establishes task force to fast-track trials on Zika virus
By PBR Staff Writer
The European Medicines Agency (EMA) has established a task force to contribute to the global response to the threat of the deadly Zika virus infection.
Production & Manufacturing > Manufacturing > News
Oxford BioMedica starts second CART programme for undisclosed indication
Oxford BioMedica has initiated work on a second Chimeric Antigen Receptor T cell (CART) programme for an undisclosed indication.
Production & Manufacturing > Manufacturing > News
Shire acquires Dyax for $5.9bn
Irish-headquartered Shire has acquired the US-based biopharmaceutical firm Dyax for about $5.9bn.
Production & Manufacturing > Manufacturing > News
Asterias transfers AST-VAC2 manufacturing process to Cancer Research UK
Asterias Biotherapeutics has completed the transfer of its manufacturing processes to produce AST-VAC2 to Cancer Research UK.
Production & Manufacturing > Manufacturing > News
Drug companies urge governments to join fight on superbugs
By PBR Staff Writer
Drug manufacturers from across the world called for governments and industry to join forces in combating superbugs, which are strains of bacteria that are resistant to various antibiotic types.
Production & Manufacturing > Manufacturing > News
Cellectis inks deal with CELLforCURE for cGMP manufacturing of UCART123
Cellectis has signed agreement with CELLforCURE for the cGMP manufacturing of UCART123 clinical batches for hematological malignancies.
Production & Manufacturing > Manufacturing > News
GlobalData says Shire's acquisition of Baxalta marks strong start to healthcare mergers and acquisitions for 2016
With Shire's acquisition of Baxalta International expected to generate sales of $20bn by 2020, the deal marks a strong start to healthcare Mergers and Acquisitions (M&A) for 2016, following on from a record-breaking year in which global transactions totaled $680bn in 2015, according to research and consulting firm GlobalData.
Production & Manufacturing > Manufacturing > News
Oxford BioMedica wins UK MHRA approval to manufacture bulk drug material at Yarnton plant
Oxford BioMedica has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to manufacture bulk drug material for Investigational Medicinal Products (IMPs) at the Group’s recently established and commissioned specialist biomanufacturing facility in Yarnton, Oxford, UK.
Production & Manufacturing > Manufacturing > News
Shire and Baxalta agree on $32bn merger
By PBR Staff Writer
Irish drugmaker Shire has agreed to merge with American biopharmaceutical firm Baxalta under a transaction worth about $32bn.
Production & Manufacturing > Manufacturing > News
Agenus acquires PhosImmune with novel class of cancer neoantigens
Agenus has acquired PhosImmune, a company that has discovered an entirely new portfolio of cancer neoantigens.
Production & Manufacturing > Manufacturing > News
Seattle Genetics and Bristol-Myers Squibb start new trial assessing combination of Adcetris and Opdivo
By PBR Staff Writer
US-based Seattle Genetics and Bristol-Myers Squibb have initiated a new trial assessing Adcetris (brentuximab vedotin) in combination with Opdivo (nivolumab).
Production & Manufacturing > Manufacturing > News
151-165 of 2220 results